
Arafura Rare Earths (ASX: ARU) is trading near a key support zone after recent volatility, where buyers have previously stepped in. Strength in rare earth prices adds sector momentum. While this mix may signal opportunity, confirmation depends on support holding and the company delivering meaningful project progress.

Appen Limited (ASX: APX), founded in 1996 and listed since 2015, is an Australian AI data specialist providing dataset sourcing, annotation, and model evaluation. Operating the Global Services and New Markets segments, it serves major tech clients across multiple industries, leveraging a 1M+ global workforce that spans 180+ languages in 130 countries.

European Lithium (ASX: EUR) has rebounded from a well-established support level on its daily chart, a move that suggests buyers continue to defend this key zone. While the company’s Wolfsberg project underpins its long-term European battery supply narrative, the recent lift is largely technical, driven by market psychology and historical buying interest.

Atlantic Lithium is holding up while many lithium explorers fall because it is further advanced toward production, with permitting progress at Ewoyaa, funding support, and improving lithium prices underpinning confidence. Strong drilling results and a clear path to FID differentiate it from early-stage peers. Technically, the stock remains in an uptrend with solid volume support, signalling accumulation rather than distribution and suggesting investors are backing execution, not just sentiment.

Silver has rebounded sharply after a brutal 30–40% pullback, driven by geopolitical tensions and renewed macro uncertainty. Against this backdrop, Investigator Resources Ltd (ASX: IVR) — whose share price has more than tripled over the past year — has pulled back from recent highs as traders de-risk. The key question now is whether silver’s renewed surge signals another leg higher, offering leveraged upside for IVR, or just more short-term volatility.

PolyNovo Limited (ASX: PNV) remains a fundamentally strong, high-growth medtech, but its share price is currently testing key support around A$0.88–0.92 within a broader sideways range. While selling pressure has eased and momentum is stabilising, a confirmed bottom would require a sustained break above A$1.08; otherwise, a fall below A$0.86–0.90 could signal further downside.